European Commission tops a billion euros invested in the fight against the global AIDS epidemic; clears new pandemic flu vaccine use
On the eve of World AIDS Day 2009 (December 1), the European Commission announced that it has invested over 1 billion euros($1.5 billion) in the fight against AIDS, tuberculosis and Malaria. As a founding member of the Global Fund to Fight AIDS, Tuberculosis and malaria, the Commission has to date pledged 1,072.5 million euros covering the period 2002-2010 and has recently made new policy commitments to do more, better, together.
According to the latest figures, new HIV infections have been reduced by 17% over the past eight years and that the most progress is seen in sub-Saharan Africa. However worldwide, the number of people living with HIV now reaches 33 million, with the fastest spread of the epidemic occurring on the threshold of the European Union, in the neighbouring countries of Eastern Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze